On Friday, UBS increased its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) to $288 from the previous $253, while reiterating its Buy rating on the company's stock. The revision follows the release of the HELIOS-B study data, which the firm believes strengthens the case for Alnylam's vutrisiran in the treatment of ATTR-CM, a cardiac condition. According to UBS, the recent insights gained from management meetings have further solidified their confidence in the commercial prospects for vutrisiran.
The firm's updated valuation reflects a more optimistic view on vutrisiran's revenue projections, particularly after the top-line results from the HELIOS-B trial became available. UBS has highlighted that Alnylam's current enterprise value to peak sales ratio makes it an attractive proposition when compared to its large-cap growth peers, such as Vertex Pharmaceuticals (NASDAQ:VRTX) and Regeneron (NASDAQ:REGN) Pharmaceuticals. The firm anticipates that Alnylam could continue to establish itself as a significant player in the biotech sector over the next one to two years, especially as it approaches profitability.
UBS also sees a sizeable market opportunity for ATTR-CM treatments, where multiple mechanisms of action, including silencers and stabilizers, could coexist. The firm believes that the HELIOS-B data positions vutrisiran to capture a meaningful market share, both as a first-line treatment and as an option for patients switching from stabilizers. Despite Alnylam's stock price increasing approximately 55% over the past week, UBS still sees further potential for growth. Detailed HELIOS-B data is expected to be presented at the European Society of Cardiology (ESC) at the end of August, which could further cement vutrisiran's strong profile.
Looking beyond the immediate prospects, UBS is optimistic about the long-term growth potential driven by Alnylam's pipeline, including zilebesiran for hypertension and other promising treatments such as mivelsiran/ALN-APP and the next-generation silencer ALN-TTRsc04. Additionally, the expansion of Alnylam's RNAi platform into treatments for muscle and adipose tissue, with Investigational New Drug (IND) applications anticipated by the end of 2025, is seen as an area of underappreciated potential.
In other recent news, Alnylam Pharmaceuticals has been the focus of several analyst adjustments following positive developments. RBC Capital Markets increased the stock's price target to $265 from $250, maintaining an Outperform rating, due to heightened confidence in Alnylam's product, Amvuttra. This change comes after impressive clinical results and Alnylam's plans to file for regulatory approval within the next three to four months.
H.C. Wainwright has also maintained its Buy rating and a $400.00 price target for Alnylam, following successful Phase 3 trial results. Morgan Stanley increased the price target for Alnylam to $250 from the previous $164, maintaining an Equalweight rating, after reviewing the HELIOS-B study results.
Alnylam's Q1 2024 revenues reached $365 million, marking a 32% increase from the same period the previous year, primarily driven by its Transthyretin (TTR) franchise. The company is targeting net product revenues between $1.4 billion and $1.5 billion for 2024.
BMO Capital maintained its positive outlook on Alnylam, reiterating an Outperform rating with a $234.00 price target.
InvestingPro Insights
Following UBS's optimistic outlook on Alnylam Pharmaceuticals, current metrics from InvestingPro provide a broader context for investors. With a substantial market capitalization of $31.24 billion, Alnylam has demonstrated a notable revenue growth of 75.2% over the last twelve months as of Q1 2023. This growth is also reflected in the short term, with a quarterly revenue increase of 54.82% in Q1 2023. Despite the company not being profitable in the last twelve months, the gross profit margin stands impressively at 83.95%, indicating efficient cost management relative to revenue.
InvestingPro Tips indicate that the stock may be in overbought territory, which could be of interest to traders looking for potential price corrections. However, the significant returns over the last week, month, and three months underscore the market's current positive reaction to Alnylam's prospects. For investors seeking a deeper analysis, InvestingPro offers additional tips, including the fact that Alnylam has been trading near its 52-week high and that analysts do not expect the company to be profitable this year. For more exclusive insights, visit https://www.investing.com/pro/ALNY and consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With 12 additional InvestingPro Tips available, investors can gain a comprehensive understanding of Alnylam's performance and potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.